Orleans Cedex 2

• EORTC-2238-GUCG: Improving impact of anti-androgen treatments on patient's daily life and their cancer Recruiting
  2023-506817-23-01 5 2025-05-23 Metastatic hormone naïve prostate cancer (mHNPC)
• MODULO Recruiting
  2024-515793-27-01 5 2025-04-30 HIV
• Beta-blOckers discoNtinuation in patients presenting heart FaIlure with REcovered left ventricular ejection fraction Recruiting
  2023-508798-94-00 5 2025-02-11 Heart failure
• NEFARTHRO - Effets précoces et tardifs du néfopam dans l'analgésie multimodale après arthroplastie totale de hanche Recruiting
  2023-504079-26-01 5 2025-02-10 Arthroplastie totale de hanche
• Combination of baricitinib and anti-TNF in rheumatoid arthritis Recruiting
  2024-511442-39-00 5 2025-02-05 Rheumatoid arthritis (RA)
• Dose individualization of chemotherapy in patients with gastrointestinal cancers lacking a specific liver enzyme Recruiting
  2023-509963-25-00 4 2025-01-17 Fluoropyrimidine (FP)-naive patients with gastrointestinal (GI) cancer
• Comparison of a personalized maintenance therapy based on the evolution of anti-desmoglein antibodies as biomarkers of pemphigus subclinical … Recruiting
  2024-514886-21-00 6 2024-11-06 Pemphigus diseases (Pemphigus Vulgaris - PV and Pemphigus Foliaceus (P
• FIRST LINE CHEMOTHERAPY FOR METASTATIC GASTRO ENTERO PANCREATIC NEUROENDOCRINE CARCINOMA Recruiting
  2024-515300-39-00 4 2024-10-18 METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA OF G
• PRODIGE 70 - CIRCULATE - CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II Recruiting
  2024-515297-27-00 5 2024-08-14 colon carcinoma
• A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients with Chro … Recruiting
  2023-508005-24-00 5 2024-08-01 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
• Phase III study to evaluate the effect of balcinrenone/dapagliflozin in patients with heart failure and impaired kidney function Recruiting
  2023-508162-15-00 5 2024-07-12 Chronic HF and comorbid impairment of kidney function who had a recent
• FILOCLL015 - GLORIFY - A phase 2 study evaluating the bispecific CD3xCD20 antibody GLOfitamab in combination with rituximab or obinutuzumab … Recruiting
  2022-501554-11-00 4 2024-03-21 Patients with previously untreated Richter’s syndrome (RS), defined as
• Weaning protocol for high-flow nasal oxygen therapy in the ICU - Multicenter randomized controlled trial. HiFloWEAN Recruiting
  2023-504366-36-00 5 2024-02-17 de novo acute respiratory failure
• Early Oseltamivir Carboxylate Low Plasma Concentration in Patients Admitted to Intensive Care for Severe Influenza. Recruiting
  2024-516058-23-00 5 2023-12-18 Adult patients admitted to the ICU for management of severe influenza
• MARSUN: Evaluation of the benefits of the combination of Mosunetuzumab-Lenalidomide versus a treatment chosen by the investigator in Patient … Recruiting
  2022-501810-77-00 5 2023-09-01 Relapsed or Refractory Marginal Zone Lymphoma
• Benefit of transplantation after Complete Response In Patients with T-cell lymphoma Recruiting
  2022-501710-62-02 6 2023-06-07 Peripheral T-cell lymphoma (PTCL)
• THINK - intensification of blood pressure lowering Therapeutics based on diuretics versus usual management for uncontrolled Hypertension IN … Recruiting
  2022-501494-39-00 5 2023-03-28 Uncontrolled Hypertension IN patients with moderate to severe chronic
• Piperacillin-tazobactam and temocillin as carbapenem-alternatives for the treatment of severe infections due to extended-spectrum beta-lacta … Recruiting
  2024-511866-36-00 5 2023-03-11 patients hospitalized in ICU with ESBL-producing Enterobacteriaceae se
• Efficacy of a sequential treatment strategy in Rheumatoid Arthritis. Recruiting
  2022-500234-29-00 5 2022-11-28 Rheumatoid Arthritis
• ASPIC - Antimicrobial Stewardship for Ventilator Associated Pneumonia in Intensive Care Recruiting
  2024-513327-16-00 5 2022-09-20 Intensive care
• CPX-351 versus intensive chemotherapy in patients with de novo intermediate or adverse risk AML stratified by genomics Recruiting
  2022-500295-60-00 4 2022-09-15 Acute Myeloid Leukemia
• A randomized phase I/ II multicenter study evaluating combination of luspatercept in LR-MDS without RS having failed or being ineligible to … Recruiting
  2024-515354-24-00 9 2022-05-18 Low risk myelodysplastic syndrom without RS having failed or being ine
• A phase II-III randomized trial evaluating maintenance pembrolizumab (± pemetrexed) until progression versus observation (± pemetrexed) afte … Recruiting
  2024-515945-40-00 10 2022-05-02 Non small cell lung cancer
• Evaluation of an initial treatment with bevacizumab in combination with chemotherapy and then in combination with niraparib in maintenance i … Recruiting
  2023-504166-37-00 4 2022-02-01 Advanced ovarian, tubal or peritoneal cancer.

Showing 49–72 of 136 trials